• Intercept Pharmaceuticals Inc., of New York, said it completed a $30 million Series C preferred stock financing led by OrbiMed Advisors LLC, with existing majority investor Genextra S.p.A. also participating.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST